Sign In
Buy SGMO
$0.216
+0.0022 (+1.03%)
At Close: Jun 03, 2026
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
04:01pm, Tuesday, 08'th Aug 2023
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND SECOND QUARTER 2023 FINANCIAL RESULTS.
7 Sorry Pharma Stocks to Sell in April Before It's Too Late
06:30am, Sunday, 16'th Apr 2023
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing
Sangamo: Hemophilia A Program With Pfizer Key To Success
02:52am, Thursday, 23'rd Mar 2023
Final results from the phase 3 AFFINE trial using giroctocogene fitelparvovec for the treatment of patients with Hemophilia A are expected in the 1st half of 2024. If phase 3 trial is successful, Pfiz
Best Penny Stocks To Buy? 3 To Watch With Targets Up To 400%
11:54am, Thursday, 23'rd Feb 2023
Analysts like these penny stocks but is it time to buy or not? The post Best Penny Stocks To Buy?
Sangamo Therapeutics, Inc. (SGMO) Q4 2022 Earnings Call Transcript
09:15pm, Wednesday, 22'nd Feb 2023
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q4 2022 Results Conference Call February 22, 2023 4:30 PM ET Company Participants Louise Wilkie - VP of IR and Corporate Communications Sandy Macrae - Chief E
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue Estimates
06:49pm, Wednesday, 22'nd Feb 2023
Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Sangamo (SGMO) is Poised for a Turnaround After Losing -17.68% in 4 Weeks
11:19am, Wednesday, 22'nd Feb 2023
The heavy selling pressure might have exhausted for Sangamo (SGMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
There's a Lot of Upside For Emerging Gene-Editing Companies
09:16am, Tuesday, 21'st Feb 2023
Gene editing may be a relatively new industry, but it already has a lot of promise, especially for savvy biotech investors. Several gene editing companies have notable upsides, meaning that no matter
Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week
11:01am, Friday, 10'th Feb 2023
These cutting-edge biotech companies quickly fell out of favor with investors this week.
7 CRISPR Stocks With the Best Long-Term Potential
07:10pm, Monday, 30'th Jan 2023
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease
3 Undervalued Penny Stocks According To Analysts
02:17pm, Friday, 16'th Dec 2022
Penny stocks to buy according to analysts. Are they right?
Sangamo Therapeutics: Ready To Dust Off My Dormant Position Ahead Of A Pivotal 2023
09:47pm, Saturday, 19'th Nov 2022
Sangamo Therapeutics is developing groundbreaking genomic and cell therapies for the treatment of some of the worst diseases known to man. I review the company's recent progress and will provide my vi
Sangamo Therapeutics, Inc. (SGMO) Q3 2022 Earnings Call Transcript
09:22pm, Thursday, 03'rd Nov 2022
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Na
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates
07:36pm, Thursday, 03'rd Nov 2022
Sangamo (SGMO) delivered earnings and revenue surprises of 2.86% and 2.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead
05:08pm, Wednesday, 31'st Aug 2022
Shares have fallen by 30% so far in 2022. Durability and safety for the Fabry disease gene therapy program continues to look best-in-class and enrollment should accelerate due to investigator enthusia
